This Analyst Sees Nearly 500% Upside in Avanir Pharmaceuticals (AVNR)
Genetics listen to the CEO's recent presentation at the Roth Healthcare conference:
ARNA is looking like another BUYING opportunity on this pull back!
Nuedexta scrips are growing currently the run rate is about $40 million dollars a year based on current scrips annualized (NUEDEXTA FDA approved about one year ago)
Pending EU Nuedexta approval; approval possible by this summer!
PH 2 Alzheimer's agitation to be launched within weeks!
MS Pain Ph 2 study underway!
Strong balance sheet!
25 million shares short with NO hedge!